New Pancreatic Cancer Drug Doubles 1-Year Survival in Phase 2 Clinical Trial
2026/05/14 | Northwestern University
National Reimbursement Decisions Delay Access for Drugs Fast-Tracked by EMA
2026/05/14 | Journal of Pharmaceutical Policy and Practice
Claims Data Suggest Lower Risk of Dementia in Seniors After High-Dose Flu Vaccine
2026/05/14 | (Neurology
Limiting Food Plastics Touchpoints Decreases Chemical Levels in 7 Days
2026/05/14 | Nature Medicine
Healthcare Reclaims Top Spot Among US Domestic Worries in Gallup Poll
2026/05/14 | Gallup
Commercial Insurance Denials of Branded Prescriptions Rise Sharply in Recent Years
2026/05/13 | IQVIA
Adherence and Quality of Life Improve After Switch to Lower-Volume Injection
2026/05/13 | Rheumatology and Therapy
Insurance Data Characterize Risk of Early Atopic Dermatitis Progressing to Asthma
2026/05/13 | Scientific Reports
Advancement of Hepatitis C Elimination in the United States Earns Inaugural 2025 ISPOR Impact Award
2026/05/13 | Value & Outcomes Spotlight
2026 Health Economics and Outcomes Research Awards Announced
2026/05/13 | ISPOR
Moving Patient Centricity Beyond Tokenism: Just Checking the Box Misses the Point
2026/05/13 | Value & Outcomes Spotlight
Themes Shaping ISPOR 2026: Policy, Pricing, and Affordability Pressures Reshaping Access
2026/05/13 | The Evidence Base
Themes Shaping ISPOR 2026: From Expanding to RWD Sources to Fit-for-Purpose RWE
2026/05/13 | The Evidence Base
Themes Shaping ISPOR 2026: Making Patient-Centered Evidence Meaningful in Decision-Making
2026/05/13 | The Evidence Base
Themes Shaping ISPOR 2026: The Growing Relevance of HEOR as a Strategic, Future-Ready Function
2026/05/13 | The Evidence Base
Exploring the ISPOR 2026 Conference Program with Dr Laura Pizzi
2026/05/06 | The Evidence Base
- 1
- 2
- 3
- 4 (current)
- 5
Subscribe to the HEOR News Desk
SubscribeAlready have an ISPOR Profile? Click here to manage your subscriptions.